Sunday, May 18, 2025
5/18/2025
Therapeutic targeting of an oncogenic translational program in AML - PROJECT SUMMARY CBFβ-SMMHC is the driver oncogene in acute myeloid leukemia (AML) with the chromosome inversion inv(16)(p13q22). CBFβ-SMMHC induces AML by sequestering RUNX1, the transcription factor that plays an important role in normal hematopoiesis. Adult inv(16) AML patients present poor clinical outcomes - 30-40% of these patients relapse and die from the disease. This suggests developing better therapeutic strategies for treating inv(16) AML is critical. We recently developed a small molecule inhibitor, AI-10-49, which specifically disrupts CBFβ-SMMHC binding to RUNX1. AI-10-49 treatment induced leukemic cell apoptosis in human primary inv(16) AML cells and enhanced survival in an inv(16) mouse model. AI-10-49 is the first targeted therapy for inv(16) AML and is under development as an anti-leukemic drug. In a recent study, we explored the mechanism of action of AI-10-49. We found that AI-10-49-induced cell death is partly mediated by inhibition of the eukaryotic translation initiation factor 4 gamma 1 (eIF4G1) in inv(16) AML cells. eIF4G1 inhibition leads to apoptosis in inv(16) AML cells, indicating eIF4G1 as a therapeutic target. We also found that reactivation of eIF4G1 is a major source of AI-10-49 resistance in inv(16) AML cells, and eIF4G1 inhibition by the small molecule inhibitor SBI- 756 can overcome drug resistance in inv(16) AML cells. Our results provide proof-of-concept for testing eIF4G1 inhibitors in combination with AI-10-49 to overcome drug resistance during treatment of inv(16) AML. Our data suggest that overexpression of eIF4G1 by CBFβ-SMMHC is a critical step in inv(16) AML transformation. We hypothesize that CBFβ-SMMHC activates eIF4G1 in inv(16) AML, altering protein synthesis and rewiring the AML proteome, which, in turn, promotes leukemogenesis and reactivation of eIF4G1, contributing to AI-10-49 resistance. We will test this hypothesis by i) characterizing the therapeutic value of SBI-756, an eIF4G1 small molecule inhibitor, in inv(16) AML cell survival using a CBFβ-SMMHC genetic mouse model and an inv(16) AML patient-derived xenograft model, and ii) defining the mechanisms of action of eIF4G1 in inv(16) AML.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).